MEK targeted cancer therapies were previously shown to induce YAP activity as a survival mechanism [36,46], where nuclear active YAP promotes tumorigenesis by inducing expression of the anti-apoptotic protein BCL-xL (BCL2L1) [46]. This evidence concerns the gene BCL2L1 and cancer.